Critical

Anti-GBM disease (Goodpasture disease; anti-glomerular basement membrane disease)

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Rare, organ-threatening autoimmune disease: antibodies to the alpha-3 chain of type IV collagen (NC1 domain) in glomerular and alveolar basement membranes cause rapidly progressive (crescentic) glomerulonephritis, often with diffuse alveolar haemorrhage (pulmonary-renal syndrome = Goodpasture syndrome). Linear IgG on immunofluorescence. A true nephrological emergency — kidney recovery depends on starting plasma exchange + immunosuppression BEFORE the patient becomes dialysis-dependent; pulmonary haemorrhage is immediately life-threatening. ~1/3 are also ANCA-positive ('double-positive').

Red flags

  • Haemoptysis/alveolar haemorrhage with hypoxia — immediately life-threatening, needs ITU + aggressive therapy
  • Oligo-anuria / dialysis dependence at presentation — poor renal prognosis (but still treat lungs)
  • Rapidly rising creatinine over days — the 'rapidly progressive' in RPGN; every hour counts
  • Double-positive anti-GBM + ANCA — relapsing course, needs vasculitis-style maintenance
  • Infection during intense immunosuppression + plasma exchange (immunoglobulin depletion)

Assessment

Differential diagnosis

  • ANCA-associated vasculitis (GPA/MPA) — other cause of pulmonary-renal syndrome and crescentic GN
  • Lupus nephritis / other immune-complex RPGN
  • Severe infection/sepsis with alveolar haemorrhage
  • Other causes of RPGN (post-infectious, IgA crescentic)
  • Cardiorenal pulmonary oedema mimicking alveolar haemorrhage

Investigations

  • Serum anti-GBM antibody (urgent) — send immediately; also ANCA (MPO/PR3) as double-positivity occurs
  • U&E/creatinine/eGFR (often markedly deranged, rapidly rising), urine microscopy (RBC casts, dysmorphic haematuria), PCR/ACR
  • FBC (iron-deficiency anaemia from alveolar bleeding), coagulation, group & save
  • CXR/CT chest (alveolar infiltrates), ABG; KCO/transfer factor RAISED in active alveolar haemorrhage
  • Renal biopsy — crescentic GN with LINEAR IgG along GBM (diagnostic); do not delay treatment awaiting biopsy if diagnosis clinically strong + serology pending
  • Baseline infection screen (HBV/HCV/HIV, TB) before immunosuppression

Management

  • Treat as an emergency the moment anti-GBM disease is strongly suspected — do not wait for biopsy if serology is pending and presentation fits (especially with pulmonary haemorrhage)
  • Start urgent PLASMA EXCHANGE to remove circulating anti-GBM antibody — daily (or alternate-day) ~until antibody undetectable (typically ~2-3 weeks); replace with albumin, and with fresh frozen plasma after sessions if pulmonary haemorrhage/recent biopsy (bleeding risk)
  • High-dose corticosteroids: pulse IV methylprednisolone then oral prednisolone taper
  • Cyclophosphamide (oral or IV) to suppress antibody production
  • Supportive care: oxygen/ventilatory support for alveolar haemorrhage, transfuse as needed, correct coagulopathy, treat/avoid infection, dose-adjust and avoid further nephrotoxins; RRT for standard AKI indications
  • Prognosticate: patients who are dialysis-dependent at presentation with 100% crescents and NO pulmonary haemorrhage rarely recover renal function — intensive immunosuppression may still be warranted for the lungs but renal recovery is unlikely; those with pulmonary haemorrhage are treated aggressively regardless of renal severity
  • Treat concurrent ANCA vasculitis if double-positive (these behave more like vasculitis with relapse risk and may need maintenance immunosuppression; pure anti-GBM rarely relapses)
  • Rituximab reserved for cyclophosphamide intolerance/failure; PCP and infection prophylaxis throughout

Drugs & doses

Plasma exchange: daily/alternate-day, ~1-1.5 plasma volumes, albumin replacement (add FFP if pulmonary haemorrhage or post-biopsy), until anti-GBM antibody undetectable (~14-21 days) [verify local protocol]
Methylprednisolone 500 mg-1 g IV once daily x3 days, then prednisolone ~1 mg/kg/day PO (max ~60-80 mg) with taper over 6-9 months [verify local dose]
Cyclophosphamide 2-3 mg/kg/day PO (reduce for age/renal function) OR pulsed IV, for ~3 months [verify local dose]
Co-trimoxazole PCP prophylaxis during immunosuppression [verify local dose]
Rituximab as alternative if cyclophosphamide not tolerated (specialist) [verify local dose]
Supportive: oxygen/ventilation, packed red cells for alveolar haemorrhage-related anaemia, RRT as indicated

Disposition

Admit immediately, usually HDU/ITU, under nephrology (+ respiratory/ITU for pulmonary haemorrhage). Requires urgent plasma exchange and immunosuppression. Early transplant work-up is deferred until anti-GBM antibody undetectable for ~6 months given recurrence risk.

Complications & pitfalls

  • Irreversible kidney failure requiring long-term dialysis/transplant
  • Fatal pulmonary haemorrhage/respiratory failure
  • Immunosuppression complications: infection, cyclophosphamide toxicity (cytopenias, haemorrhagic cystitis, gonadotoxicity, malignancy)
  • Plasma-exchange complications (bleeding, line sepsis, citrate/coagulation effects)
  • Relapse (uncommon in pure anti-GBM, more with double-positivity)

Exam pearls

  • Time is nephrons: outcomes hinge on starting plasma exchange + steroids + cyclophosphamide BEFORE dialysis dependence — strong clinical suspicion plus pending serology justifies starting treatment before the biopsy result.
  • Triad to recognise: pulmonary-renal syndrome (haemoptysis + RPGN) with LINEAR IgG on biopsy and positive serum anti-GBM.
  • Always co-send ANCA: ~1 in 3 are double-positive and relapse like vasculitis, needing maintenance immunosuppression that pure anti-GBM does not.
  • Dialysis-dependent at presentation with 100% crescents and no lung bleeding = renal recovery very unlikely; reserve the most aggressive renal-directed therapy for salvageable kidneys, but treat alveolar haemorrhage aggressively regardless.
  • A raised KCO/transfer factor helps confirm active alveolar haemorrhage.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.